human MT2 cells |
Function assay |
1 ug/mL |
4 days |
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production at 1 ug/mL after 4 days by ELISA |
21168336 |
human MOLT4 cells |
Function assay |
1000 nM |
|
Inhibition of Mab 12G5 binding to CXCR4 expressed in human MOLT4 cells at 1000 nM by FACS analysis |
19451305 |
human U87 cells |
Function assay |
1000 nM |
|
Antagonist activity at CXCR4 in human U87 cells assessed as inhibition of SDF1-induced modulation of cAMP production at 1000 nM by TR-FRET assay |
17958344 |
human MT4 cells |
Function assay |
|
4 days |
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus replication after 4 days by MTT assay, EC50=4 nM |
20043638 |
HEK293 cells |
Function assay |
|
2 days |
Antiviral activity against T20-resistant HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of viral replication after 2 days, IC50=2.3 nM |
19451305 |
U87 |
Function assay |
|
15 mins |
Antagonist activity at human CXCR4 expressed in human U87 cells expressing CD4 assessed as inhibition of CXCL12-induced cAMP production pretreated for 15 mins before forskolin challenge by TR-FRET analysis, IC50=0.695μM |
21105715 |
MT4 |
Antiviral assay |
|
5 days |
Antiviral activity against HIV1 infected in MT4 cells expressing CXCR4 assessed as inhibition of virus-induced cytopathic effect after 5 days, EC50=0.002μM |
22909088 |
CD44null |
Function assay |
|
7 days |
Effect on human GBM2 cell differentiation assessed as increase in CD44null cells after 7 days by flow cytometric analysis |
22909088 |
CD44null |
Function assay |
|
7 days |
Effect on human GBM1 cell differentiation assessed as increase in CD44null cells after 7 days by flow cytometric analysis |
22909088 |
CEM-SS cells |
Function assay |
|
|
Effective concentration of compound against HIV-1 LAI strain in CEM-SS cells, EC50=127 nM |
14698189 |
rat IR983F cells |
Function assay |
|
|
Displacement of [125I]CXCL12 from CXCR4 in rat IR983F cells, IC50=108 nM |
19053768 |
MT-4 cells |
Function assay |
|
|
Effective concentration of compound against HIV-1 IIIB strain in MT-4 cells, EC50=65 nM |
14698189 |
human Jurkat cells |
Function assay |
|
|
Antagonist activity at CXCR4 in human Jurkat cells assessed as inhibition of SDF1-induced cell migration, IC50=27.4 nM |
19188071 |
PBMC cells |
Function assay |
|
|
Effective concentration of compound against HIV-1 89.6 strain in PBMC cells, EC50=3.8 nM |
14698189 |
GHOST CXCR4 cell line |
Function assay |
|
|
Inhibitory concentration of compound against HIV-1 LAI strain in GHOST CXCR4 cell line, IC50=0.95 nM |
14698189 |
CHOK1 cells |
Function assay |
|
|
Displacement of [125I]SDF1alpha from CXCR4 expressed in CHOK1 cells, IC50=0.81 nM |
17715128 |
human HL60 cells |
Function assay |
|
|
Displacement of [125I]SDF1alpha from CXCR4 in human HL60 cells, IC50=15.2 μM |
19188071 |
MT4 |
Antiviral assay |
|
|
Antiviral activity against HIV1 3B assessed as reduction in cytopathic effect in MT4 cells, EC50=0.011μM |
17034122 |
MT4 |
Antiviral assay |
|
|
Antiviral activity against X4-tropic HIV1 NL4.3 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity, EC50=0.062μM |
22579418 |
CHO |
Function assay |
|
|
Binding affinity to human recombinant CXCR4 expressed in CHO cells, Kb=0.077μM |
22909088 |
CHO |
Function assay |
|
|
Antagonist activity at human recombinant CXCR4 expressed in CHO cells assessed as inhibition of SDF1a-induced electrical impedance by dielectric spectroscopic analysis, IC50=0.26μM |
22909088 |